From: PSMD9 expression predicts radiotherapy response in breast cancer
Characteristic | Category | Number of cases (%) |
---|---|---|
Age (years) | Median: 59 | Â |
Range: 31-93 | ||
Surgery | Wide local excision | 89 (56.7) |
Mastectomy | 68 (43.3) | |
Grade | 1 | 29 (18.5) |
2 | 73 (46.5) | |
3 | 55 (35.0) | |
Size (cm) | <2 | 73 (46.5) |
2-5 | 69 (43.9) | |
>5 | 15 (9.6) | |
Hormone receptors | ER + | 111 (70.7) |
ER - | 46 (29.2) | |
HER2 + | 4 (2.5) | |
HER2 - | 18 (11.5) | |
HER2 unknown | 135 (86.0) | |
LN status (number positive nodes) | 0 | 86 (54.8) |
1-3 | 40 (25.5) | |
4+ | 26 (16.6) | |
Unknown | 5 (3.2) | |
Adjuvant therapy | Chemotherapy | 40 (25.5) |
No chemotheray | 117 (74.5) | |
Endocrine | 115 (73.2) | |
No endocrine | 29 (18.5) | |
Endocrine unknown | 13 (8.3) | |
RT | 110 (70.1) | |
No RT | 47 (29.9) | |
Local recurrence | Yes | 32 (20.4) |
No | 125 (79.6) | |
Systemic recurrence | Yes | 49 (31.2) |
No | 108 (68.8) | |
Follow-up (months) | Median: 96 | Â |
Range: 9-220 |